Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Nucleic Acids Research
|
November 24, 2011
GeneSigDB: a manually curated database and resource for analysis of gene expression signatures
Aedín C Culhane, Markus S Schröder, Razvan Sultana, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Science Translational Medicine
|
July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.
The Journal of Molecular Diagnostics : JMD
|
December 4, 2014
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens
Christopher D Carey, Daniel Gusenleitner, Bjoern Chapuy, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Blood
|
January 17, 2016
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, et al.
Nature Cancer
|
July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer
|
August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
The Journal of Molecular Diagnostics : JMD
|
September 26, 2024
Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance in a Training and Verification Cohort
Emily S Winn-Deen, Laura T Bortolin, Daniel Gusenleitner, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Nucleic Acids Research
|
November 24, 2011
GeneSigDB: a manually curated database and resource for analysis of gene expression signatures
Aedín C Culhane, Markus S Schröder, Razvan Sultana, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Science Translational Medicine
|
July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.
The Journal of Molecular Diagnostics : JMD
|
December 4, 2014
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens
Christopher D Carey, Daniel Gusenleitner, Bjoern Chapuy, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Blood
|
January 17, 2016
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, et al.
Nature Cancer
|
July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer
|
August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
The Journal of Molecular Diagnostics : JMD
|
September 26, 2024
Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance in a Training and Verification Cohort
Emily S Winn-Deen, Laura T Bortolin, Daniel Gusenleitner, et al.
Page
of 3